TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00136604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hib-MenAC
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax ACWY
Description: GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax ACWY
Description: GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax ACWY
Description: GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hiberix
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hiberix
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hiberix
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningitec
Description: Wyeth's MenC CRM197 conjugated vaccine, Meningitec
Study: NCT03004248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins, Type A
Description: Intramuscular Injection
Study: NCT02798614

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10-day cast
Description: Removal of plaster cast fixation 10 days after reduction
Study: NCT01309893

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Lens
Description: Lenses worn on a daily wear basis for one week
Study: NCT02408770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: selective progesterone receptor modulator
Study: NCT01733693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
Study: NCT00972257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment with dorzolamide/timolol
Description: 24-hour IOP control with the two fixed combinations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment with brimonidine/timolol
Description: 24-hour pressure control with brimonidine/timolol
Study: NCT04614272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prayer
Description: Prayer is a non-pharmaceutical method of pain management and a form of alternative medicine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prayer
Description: Prayer is a non-pharmaceutical method of pain management and a form of alternative medicine.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Reading a poem
Description: Reading is a distraction tool for pain management
Study: NCT04212065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine
Description: To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine
Description: To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.
Study: NCT03222609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral
Study: NCT02845596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: cyclosporine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: cyclosporine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Matched Unrelated Donor Hematopoietic Stem Cell Transplant
Description: Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: horse anti-thymocyte globulin (ATG)
Description: horse anti-thymocyte globulin (ATG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabbit anti-thymocyte globulin (ATG)
Description: rabbit anti-thymocyte globulin (ATG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine
Description: fludarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: cyclophosphamide

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-dose total body irradiation (TBI)
Description: low-dose total body irradiation (TBI)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immunosuppressive Therapy (IST)
Description: Immunosuppressive Therapy (IST)
Study: NCT03586232

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arnica Montana
Description: Arnica Montana is from the Asteraceae plant family and is native to the mountain areas in Europe and western North America. It is reported to have anti-inflammatory, antiseptic, and vasodilatory properties and is often used in plastic surgery to help reduce pain, edema, and ecchymosis postoperatively.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arnica Montana
Description: Arnica Montana is from the Asteraceae plant family and is native to the mountain areas in Europe and western North America. It is reported to have anti-inflammatory, antiseptic, and vasodilatory properties and is often used in plastic surgery to help reduce pain, edema, and ecchymosis postoperatively.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bromelain
Description: Bromelain is a protease enzyme derived from the pineapple plant, Ananas comosus, which has been used to reduce swelling, inflammation, and pain and may help to reduce wound healing time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A pharmacologically inert preparation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pharmacologically inert preparation
Study: NCT03384485

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: antiphospholipid syndrome
Description: blood test for enzyme test,plasma and Lys-3-3 plasma
Study: NCT01309893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Lens
Description: Lenses worn on a daily wear basis for one week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua lens
Description: Lenses worn on a daily wear basis for one week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Optix Aqua lens
Description: Lenses worn on a daily wear basis for one week
Study: NCT00327470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaptanib Sodium 0.3 mg
Description: Pegaptanib Sodium dosed every 6 weeks in affected eye.
Study: NCT04397887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-surgical varicocelectomy
Description: Sub-inguinal micro-surgical varicocelectomy
Study: NCT02576834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Services as Usual
Description: Services as usually provided in the community

Intervention type: OTHER
Group type: OTHER
Intervention: Services as Usual
Description: Services as usually provided in the community
Study: NCT01648179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 (mesylate salt) Powder for Injection
Description: 1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 (freebase) tablets
Description: 500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 (mesylate salt) Powder for Oral Solution
Description: 1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 (freebase) tablets FED
Description: Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
Study: NCT03518164

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allograft
Description: Bone graft
Study: NCT01412918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Inhibitor™ Tinnitus Masking Device
Description: The Inhibitor™ Tinnitus Masking Device
Study: NCT01690338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium Bromide
Description: Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Administrative protocol of rocuronium is determined by each caregiver's clinical experience.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium
Description: Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
Study: NCT03900962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based resistance training
Description: Patients completed two home-based resistance training sessions each week on non-consecutive days for 12 weeks. The programme was delivered online via individual playlists on Youtube (YouTube, San Bruno, California, USA), with each playlist involving an individually-prescribed series of pre-recorded exercise videos. Each session involved a dynamic warm-up followed by 11 resistance exercises using body weight and resistance bands, and finished with static stretching. Participants completed 1-2 sets of 5-12 repetitions at 4-7 on a modified 10-point rating of perceived exertion scale, which corresponded to qualitative descriptors of moderate to hard. Resistance training stimuli were progressed weekly by increasing the external load, modifying the exercise selection, increasing the number of repetitions, and/or increasing the number of sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based resistance training
Description: Patients completed two home-based resistance training sessions each week on non-consecutive days for 12 weeks. The programme was delivered online via individual playlists on Youtube (YouTube, San Bruno, California, USA), with each playlist involving an individually-prescribed series of pre-recorded exercise videos. Each session involved a dynamic warm-up followed by 11 resistance exercises using body weight and resistance bands, and finished with static stretching. Participants completed 1-2 sets of 5-12 repetitions at 4-7 on a modified 10-point rating of perceived exertion scale, which corresponded to qualitative descriptors of moderate to hard. Resistance training stimuli were progressed weekly by increasing the external load, modifying the exercise selection, increasing the number of repetitions, and/or increasing the number of sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking intervention
Description: After the initial baseline assessment, participants recorded the number of steps they walked daily for seven days using a waist-worn pedometer. Participants maintained their usual physical activity levels during this period. Participants were then encouraged to increase their total steps walked each day by 5% each week during the 12-week intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking intervention
Description: After the initial baseline assessment, participants recorded the number of steps they walked daily for seven days using a waist-worn pedometer. Participants maintained their usual physical activity levels during this period. Participants were then encouraged to increase their total steps walked each day by 5% each week during the 12-week intervention.
Study: NCT05301712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride 5.0mg/5ml
Description: * Initial dose: 4mg, Intravenous injection~* Continuous dose: 8mg(mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4mg+8mg/day\*7=60mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 45mg/5ml
Description: * Initial dose: 4ml, Intravenous injection~* Continuous dose: 8ml (mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4ml+8ml/day\*7=60ml
Study: NCT02355977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: Periocline dental ointment
Study: NCT02544984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
Study: NCT03398915

Intervention type: PROCEDURE
Intervention: Transpedicular Instrumentation
Description: Transpedicular screw placement and instrumentation
Study: NCT02927639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyDiaText
Description: The intervention will consist of daily text messages sent to the subject's personal mobile device.
Study: NCT03006757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: titanium dioxide denture base

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: titanium dioxide denture base
Study: NCT00586989

Intervention type: PROCEDURE
Intervention: Upper endoscopy with biopsy
Description: Endoscopy with biopsy 6 weeks after the initial endoscopy
Study: NCT02275143

Intervention type: RADIATION
Intervention: CT TAP Scan
Description: Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
Study: NCT04340063

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gait training performed on a treadmill
Description: Participants randomized to the Control group will complete high intensity gait training on a treadmill.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training performed in a Movement Amplification Environment
Description: The Experimental group will perform all gait training within the movement amplification environment. To create the movement amplification environment, the investigators have constructed a cable-driven robot, the Agility Trainer. The Agility Trainer applies small forces to the pelvis that increase the difficulty to maintain forward walking
Study: NCT03398915

Intervention type: PROCEDURE
Intervention: Transpedicular Instrumentation
Description: Transpedicular screw placement and instrumentation

Intervention type: PROCEDURE
Intervention: Transpedicular Instrumentation
Description: Transpedicular screw placement and instrumentation
Study: NCT04017741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Depo-Medrone and Lidocaine
Description: Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.~Patients who no longer receive any benefit will be crossed over to the placebo arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined Depo-Medrone and Lidocaine
Description: Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.~Patients who no longer receive any benefit will be crossed over to the placebo arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
Study: NCT01544491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids
Study: NCT04475848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6953958
Description: Part 1: RO6953958 will be administered in an adaptive manner. The starting dose is planned to be 5 milligrams (mg).~Part 2: The starting dose is planned to be 45 mg.~Part 3: RO6953958 will be administered QD following a standardized breakfast on Day 3 to Day 14 at the maximum dose QD that was tested in the ongoing Part 2 (MAD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6953958
Description: Part 1: RO6953958 will be administered in an adaptive manner. The starting dose is planned to be 5 milligrams (mg).~Part 2: The starting dose is planned to be 45 mg.~Part 3: RO6953958 will be administered QD following a standardized breakfast on Day 3 to Day 14 at the maximum dose QD that was tested in the ongoing Part 2 (MAD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6953958
Description: Part 1: RO6953958 will be administered in an adaptive manner. The starting dose is planned to be 5 milligrams (mg).~Part 2: The starting dose is planned to be 45 mg.~Part 3: RO6953958 will be administered QD following a standardized breakfast on Day 3 to Day 14 at the maximum dose QD that was tested in the ongoing Part 2 (MAD).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1: A placebo will be administered in an adaptive manner. The starting dose is planned to be 5 mg.~Part 2: The starting dose is planned to be 45 mg.
Study: NCT02544984

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
Study: NCT04953455

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02775851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04953455

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03739983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Renewal Program
Description: Therapeutic vibrating wand.
Study: NCT02775851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT02355977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline
Description: Periocline dental ointment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surface and root planning
Description: surface and root planning

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surface and root planning
Description: surface and root planning